Jonathan Ang, MD
Critical Care Medicine · Columbia, MONPI 1780956862
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $436 of the $533 with a category attached, or 81.9%. 8 manufacturers reported payments, led by Veran Medical Technologies, Inc. at 24.6% of the total. Reporting peaked in 2019 at $348 and has fallen 78.6% since, to $74 in 2024.
Across 9 payments — averaging $59.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veran Medical Technologies, Inc.$131
- Johnson & Johnson$121
- Sanofi-aventis U.S. LLC$97
- Inari Medical, Inc.$96
- Grifols USA, LLC$27
- Philips North America LLC$25
- plus $37 from 2 others
What the payments were for
- Food & beverage$43682%
- Education$9718%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veran Medical Technologies, Inc. | 2 | $131 |
| Johnson & Johnson | 1 | $121 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Inari Medical, Inc. | 1 | $96 |
| Grifols USA, LLC | 1 | $27 |
| Philips North America LLC | 1 | $25 |
| Merck | 1 | $23 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$533 in reported general payments places this provider in the 70th percentile of 208 critical care medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $44,200 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $34,184 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $12,934 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,872 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,076 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $886 |
| Omeprazole | 55 | $831 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $628 |
| Montelukast Sodium | 39 | $216 |
| Prednisone | 13 | $34 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Columbia
- Yuji ObaColumbia$14K
- Tinashe MadukeColumbia$13K
- Stephanie WhitbeyColumbia$12K
- Stevan WhittColumbia$8K
- Ramez SunnaColumbia$5K
- Satish Kalanjeri BalasubramanianColumbia$5K
- Jeremy JohnsonColumbia$3K
- Kevin McKillionColumbia$2K
- Ricardo HernandezColumbia$2K
- Sachin PatilColumbia$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.